Soleno Therapeutics Inc (SLNO) concluded trading on Thursday at a closing price of $80.32, with 5.64 million shares of worth about $453.24 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 74.99% during that period and on July 10, 2025 the price saw a loss of about -9.23%. Currently the company’s common shares owned by public are about 48.53M shares, out of which, 41.76M shares are available for trading.
Stock saw a price change of -6.83% in past 5 days and over the past one month there was a price change of 3.33%. Year-to-date (YTD), SLNO shares are showing a performance of 89.39% which increased to 78.69% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $41.50 but also hit the highest price of $90.32 during that period. The average intraday trading volume for Soleno Therapeutics Inc shares is 986.20K. The stock is currently trading -2.69% below its 20-day simple moving average (SMA20), while that difference is up 2.50% for SMA50 and it goes to 35.94% higher than SMA200.
Soleno Therapeutics Inc (NASDAQ: SLNO) currently have 48.53M outstanding shares and institutions hold larger chunk of about 94.56% of that.
The stock has a current market capitalization of $4.05B and its 3Y-monthly beta is at -2.56. It has posted earnings per share of -$4.62 in the same period. It has Quick Ratio of 19.64 while making debt-to-equity ratio of 0.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SLNO, volatility over the week remained 4.92% while standing at 4.00% over the month.
Stock’s fiscal year EPS is expected to rise by 39.95% while it is estimated to increase by 156.04% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by TD Cowen on June 23, 2025 offering a Buy rating for the stock and assigned a target price of $110 to it. Coverage by Stifel stated Soleno Therapeutics Inc (SLNO) stock as a Buy in their note to investors on March 05, 2025, suggesting a price target of $74 for the stock. On December 02, 2024, Stifel Reiterated their recommendations, while on December 02, 2024, Robert W. Baird Reiterated their ratings for the stock with a price target of $72. Stock get a Buy rating from H.C. Wainwright on September 03, 2024.
